CN114588154A - 用于治疗水肿的组合物和方法 - Google Patents
用于治疗水肿的组合物和方法 Download PDFInfo
- Publication number
- CN114588154A CN114588154A CN202210078205.6A CN202210078205A CN114588154A CN 114588154 A CN114588154 A CN 114588154A CN 202210078205 A CN202210078205 A CN 202210078205A CN 114588154 A CN114588154 A CN 114588154A
- Authority
- CN
- China
- Prior art keywords
- lymphatic
- tacrolimus
- mice
- cells
- treated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 32
- 206010030113 Oedema Diseases 0.000 title claims abstract description 30
- 238000000034 method Methods 0.000 title abstract description 70
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 106
- 230000001926 lymphatic effect Effects 0.000 claims description 176
- 229960003073 pirfenidone Drugs 0.000 claims description 128
- ISWRGOKTTBVCFA-UHFFFAOYSA-N pirfenidone Chemical compound C1=C(C)C=CC(=O)N1C1=CC=CC=C1 ISWRGOKTTBVCFA-UHFFFAOYSA-N 0.000 claims description 128
- 208000027418 Wounds and injury Diseases 0.000 claims description 69
- 230000006378 damage Effects 0.000 claims description 62
- 208000014674 injury Diseases 0.000 claims description 56
- 239000002674 ointment Substances 0.000 claims description 15
- 239000007788 liquid Substances 0.000 claims description 7
- 239000006210 lotion Substances 0.000 claims description 7
- 239000000725 suspension Substances 0.000 claims description 7
- 241000195940 Bryophyta Species 0.000 claims description 6
- 239000006260 foam Substances 0.000 claims description 6
- 239000000499 gel Substances 0.000 claims description 6
- 235000011929 mousse Nutrition 0.000 claims description 6
- 239000006072 paste Substances 0.000 claims description 6
- 239000007921 spray Substances 0.000 claims description 6
- 239000006071 cream Substances 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 3
- 239000000839 emulsion Substances 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 239000000243 solution Substances 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000004922 lacquer Substances 0.000 claims 1
- 239000007901 soft capsule Substances 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 abstract description 43
- 238000011200 topical administration Methods 0.000 abstract description 12
- 241000699670 Mus sp. Species 0.000 description 177
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 168
- 229960001967 tacrolimus Drugs 0.000 description 168
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 168
- 238000011282 treatment Methods 0.000 description 165
- 206010025282 Lymphoedema Diseases 0.000 description 140
- 208000002502 lymphedema Diseases 0.000 description 140
- 210000004027 cell Anatomy 0.000 description 138
- 229960000830 captopril Drugs 0.000 description 136
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 136
- 241001465754 Metazoa Species 0.000 description 126
- 210000001365 lymphatic vessel Anatomy 0.000 description 111
- UTNUDOFZCWSZMS-YFHOEESVSA-N teriflunomide Chemical compound C\C(O)=C(/C#N)C(=O)NC1=CC=C(C(F)(F)F)C=C1 UTNUDOFZCWSZMS-YFHOEESVSA-N 0.000 description 94
- 229960000331 teriflunomide Drugs 0.000 description 94
- 210000003141 lower extremity Anatomy 0.000 description 83
- 238000011002 quantification Methods 0.000 description 81
- 230000000699 topical effect Effects 0.000 description 79
- 239000003795 chemical substances by application Substances 0.000 description 76
- 210000001519 tissue Anatomy 0.000 description 76
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 70
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 69
- 210000001744 T-lymphocyte Anatomy 0.000 description 58
- 210000001165 lymph node Anatomy 0.000 description 56
- 210000004324 lymphatic system Anatomy 0.000 description 55
- 230000001965 increasing effect Effects 0.000 description 52
- 230000002829 reductive effect Effects 0.000 description 52
- 230000006870 function Effects 0.000 description 48
- 206010016654 Fibrosis Diseases 0.000 description 47
- 230000004761 fibrosis Effects 0.000 description 47
- 230000014509 gene expression Effects 0.000 description 47
- 230000009467 reduction Effects 0.000 description 39
- 238000001356 surgical procedure Methods 0.000 description 39
- 241000581650 Ivesia Species 0.000 description 38
- 239000003981 vehicle Substances 0.000 description 37
- 230000035508 accumulation Effects 0.000 description 34
- 238000009825 accumulation Methods 0.000 description 34
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 34
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical class O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 34
- 102000012422 Collagen Type I Human genes 0.000 description 33
- 108010022452 Collagen Type I Proteins 0.000 description 33
- 229960000681 leflunomide Drugs 0.000 description 33
- 230000035168 lymphangiogenesis Effects 0.000 description 32
- 238000004458 analytical method Methods 0.000 description 31
- 238000002679 ablation Methods 0.000 description 30
- 230000008021 deposition Effects 0.000 description 28
- 206010061218 Inflammation Diseases 0.000 description 27
- 230000004054 inflammatory process Effects 0.000 description 27
- 238000005086 pumping Methods 0.000 description 26
- 229960004657 indocyanine green Drugs 0.000 description 25
- MOFVSTNWEDAEEK-UHFFFAOYSA-M indocyanine green Chemical compound [Na+].[O-]S(=O)(=O)CCCCN1C2=CC=C3C=CC=CC3=C2C(C)(C)C1=CC=CC=CC=CC1=[N+](CCCCS([O-])(=O)=O)C2=CC=C(C=CC=C3)C3=C2C1(C)C MOFVSTNWEDAEEK-UHFFFAOYSA-M 0.000 description 25
- 210000003491 skin Anatomy 0.000 description 25
- 206010028980 Neoplasm Diseases 0.000 description 23
- 230000000694 effects Effects 0.000 description 23
- 230000008595 infiltration Effects 0.000 description 23
- 238000001764 infiltration Methods 0.000 description 23
- 201000011510 cancer Diseases 0.000 description 22
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 19
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 19
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 19
- 206010042674 Swelling Diseases 0.000 description 19
- 201000010099 disease Diseases 0.000 description 19
- 230000008961 swelling Effects 0.000 description 19
- 241000699666 Mus <mouse, genus> Species 0.000 description 18
- 210000004969 inflammatory cell Anatomy 0.000 description 18
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 17
- 102000011779 Nitric Oxide Synthase Type II Human genes 0.000 description 17
- 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 17
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 17
- 239000003642 reactive oxygen metabolite Substances 0.000 description 17
- 108010074328 Interferon-gamma Proteins 0.000 description 16
- 206010052428 Wound Diseases 0.000 description 16
- 239000003814 drug Substances 0.000 description 16
- 210000003414 extremity Anatomy 0.000 description 16
- 238000010166 immunofluorescence Methods 0.000 description 16
- 230000002265 prevention Effects 0.000 description 16
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 description 16
- 108010053100 Vascular Endothelial Growth Factor Receptor-3 Proteins 0.000 description 15
- 102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 description 15
- 229940079593 drug Drugs 0.000 description 15
- 230000005764 inhibitory process Effects 0.000 description 15
- 230000003447 ipsilateral effect Effects 0.000 description 15
- 210000002540 macrophage Anatomy 0.000 description 15
- 210000004872 soft tissue Anatomy 0.000 description 15
- 230000003247 decreasing effect Effects 0.000 description 14
- 208000035475 disorder Diseases 0.000 description 14
- 210000002216 heart Anatomy 0.000 description 14
- 239000003550 marker Substances 0.000 description 14
- 210000004049 perilymph Anatomy 0.000 description 14
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 13
- 102100037850 Interferon gamma Human genes 0.000 description 13
- 108010073923 Vascular Endothelial Growth Factor C Proteins 0.000 description 13
- 102000009520 Vascular Endothelial Growth Factor C Human genes 0.000 description 13
- 210000004443 dendritic cell Anatomy 0.000 description 13
- 102000004127 Cytokines Human genes 0.000 description 12
- 108090000695 Cytokines Proteins 0.000 description 12
- 238000009169 immunotherapy Methods 0.000 description 12
- 230000001976 improved effect Effects 0.000 description 12
- 230000004044 response Effects 0.000 description 12
- 238000010186 staining Methods 0.000 description 12
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 11
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 11
- 210000005073 lymphatic endothelial cell Anatomy 0.000 description 11
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 11
- 238000011161 development Methods 0.000 description 10
- 230000018109 developmental process Effects 0.000 description 10
- 238000002224 dissection Methods 0.000 description 10
- 238000007920 subcutaneous administration Methods 0.000 description 10
- 230000032258 transport Effects 0.000 description 10
- COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 9
- 108010007859 Lisinopril Proteins 0.000 description 9
- 241000699660 Mus musculus Species 0.000 description 9
- 241000283973 Oryctolagus cuniculus Species 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 229960003699 evans blue Drugs 0.000 description 9
- 230000003176 fibrotic effect Effects 0.000 description 9
- 229960002394 lisinopril Drugs 0.000 description 9
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 description 9
- 238000010172 mouse model Methods 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 238000002560 therapeutic procedure Methods 0.000 description 9
- 238000011830 transgenic mouse model Methods 0.000 description 9
- 101800000733 Angiotensin-2 Proteins 0.000 description 8
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 description 8
- 206010006187 Breast cancer Diseases 0.000 description 8
- 208000026310 Breast neoplasm Diseases 0.000 description 8
- 239000002083 C09CA01 - Losartan Substances 0.000 description 8
- 239000002947 C09CA04 - Irbesartan Substances 0.000 description 8
- 239000005537 C09CA07 - Telmisartan Substances 0.000 description 8
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 8
- 108010036949 Cyclosporine Proteins 0.000 description 8
- 239000005475 Fimasartan Substances 0.000 description 8
- VXFJYXUZANRPDJ-WTNASJBWSA-N Trandopril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@H]2CCCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 VXFJYXUZANRPDJ-WTNASJBWSA-N 0.000 description 8
- 229950006323 angiotensin ii Drugs 0.000 description 8
- 230000003510 anti-fibrotic effect Effects 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 229960004530 benazepril Drugs 0.000 description 8
- 230000001413 cellular effect Effects 0.000 description 8
- 229960001265 ciclosporin Drugs 0.000 description 8
- 229960005025 cilazapril Drugs 0.000 description 8
- HHHKFGXWKKUNCY-FHWLQOOXSA-N cilazapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N2[C@@H](CCCN2CCC1)C(O)=O)=O)CC1=CC=CC=C1 HHHKFGXWKKUNCY-FHWLQOOXSA-N 0.000 description 8
- 229930182912 cyclosporin Natural products 0.000 description 8
- 230000002500 effect on skin Effects 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 229960003489 fimasartan Drugs 0.000 description 8
- AMEROGPZOLAFBN-UHFFFAOYSA-N fimasartan Chemical compound CCCCC1=NC(C)=C(CC(=S)N(C)C)C(=O)N1CC1=CC=C(C=2C(=CC=CC=2)C=2NN=NN=2)C=C1 AMEROGPZOLAFBN-UHFFFAOYSA-N 0.000 description 8
- 238000000684 flow cytometry Methods 0.000 description 8
- 230000002757 inflammatory effect Effects 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 229960002198 irbesartan Drugs 0.000 description 8
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 description 8
- 229960004773 losartan Drugs 0.000 description 8
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 8
- 230000007246 mechanism Effects 0.000 description 8
- VTRAEEWXHOVJFV-UHFFFAOYSA-N olmesartan Chemical compound CCCC1=NC(C(C)(C)O)=C(C(O)=O)N1CC1=CC=C(C=2C(=CC=CC=2)C=2NN=NN=2)C=C1 VTRAEEWXHOVJFV-UHFFFAOYSA-N 0.000 description 8
- 229960002582 perindopril Drugs 0.000 description 8
- IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 description 8
- 229960005330 pimecrolimus Drugs 0.000 description 8
- KASDHRXLYQOAKZ-ZPSXYTITSA-N pimecrolimus Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@@H](Cl)[C@H](OC)C1 KASDHRXLYQOAKZ-ZPSXYTITSA-N 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 229960001455 quinapril Drugs 0.000 description 8
- JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 229960005187 telmisartan Drugs 0.000 description 8
- 229940099456 transforming growth factor beta 1 Drugs 0.000 description 8
- 102400000345 Angiotensin-2 Human genes 0.000 description 7
- 239000004072 C09CA03 - Valsartan Substances 0.000 description 7
- 239000002053 C09CA06 - Candesartan Substances 0.000 description 7
- 108010061435 Enalapril Proteins 0.000 description 7
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 7
- 239000005480 Olmesartan Substances 0.000 description 7
- 229960004669 basiliximab Drugs 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 229960000932 candesartan Drugs 0.000 description 7
- SGZAIDDFHDDFJU-UHFFFAOYSA-N candesartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SGZAIDDFHDDFJU-UHFFFAOYSA-N 0.000 description 7
- 229960000873 enalapril Drugs 0.000 description 7
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 7
- 238000003384 imaging method Methods 0.000 description 7
- 229960001195 imidapril Drugs 0.000 description 7
- KLZWOWYOHUKJIG-BPUTZDHNSA-N imidapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1C(N(C)C[C@H]1C(O)=O)=O)CC1=CC=CC=C1 KLZWOWYOHUKJIG-BPUTZDHNSA-N 0.000 description 7
- 210000000066 myeloid cell Anatomy 0.000 description 7
- 229960005117 olmesartan Drugs 0.000 description 7
- 230000001575 pathological effect Effects 0.000 description 7
- 238000003752 polymerase chain reaction Methods 0.000 description 7
- 229960003401 ramipril Drugs 0.000 description 7
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 description 7
- 238000007910 systemic administration Methods 0.000 description 7
- 239000012049 topical pharmaceutical composition Substances 0.000 description 7
- 229960004699 valsartan Drugs 0.000 description 7
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 description 7
- 230000008728 vascular permeability Effects 0.000 description 7
- BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 description 6
- 102000008186 Collagen Human genes 0.000 description 6
- 108010035532 Collagen Proteins 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 239000013543 active substance Substances 0.000 description 6
- 238000010171 animal model Methods 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 230000001684 chronic effect Effects 0.000 description 6
- 208000037976 chronic inflammation Diseases 0.000 description 6
- 230000006020 chronic inflammation Effects 0.000 description 6
- 230000008045 co-localization Effects 0.000 description 6
- 229920001436 collagen Polymers 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 210000003722 extracellular fluid Anatomy 0.000 description 6
- 229960002490 fosinopril Drugs 0.000 description 6
- 210000002443 helper t lymphocyte Anatomy 0.000 description 6
- 230000036039 immunity Effects 0.000 description 6
- 230000028709 inflammatory response Effects 0.000 description 6
- 230000003902 lesion Effects 0.000 description 6
- 230000004807 localization Effects 0.000 description 6
- 230000000492 lymphangiogenic effect Effects 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 229960002769 zofenopril Drugs 0.000 description 6
- IAIDUHCBNLFXEF-MNEFBYGVSA-N zofenopril Chemical compound C([C@@H](C)C(=O)N1[C@@H](C[C@@H](C1)SC=1C=CC=CC=1)C(O)=O)SC(=O)C1=CC=CC=C1 IAIDUHCBNLFXEF-MNEFBYGVSA-N 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 102100037907 High mobility group protein B1 Human genes 0.000 description 5
- 102000003816 Interleukin-13 Human genes 0.000 description 5
- 108090000176 Interleukin-13 Proteins 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 5
- 229940096422 collagen type i Drugs 0.000 description 5
- 210000004087 cornea Anatomy 0.000 description 5
- 230000004069 differentiation Effects 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 239000003102 growth factor Substances 0.000 description 5
- 238000003125 immunofluorescent labeling Methods 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 210000002751 lymph Anatomy 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000007170 pathology Effects 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 230000010349 pulsation Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 210000002460 smooth muscle Anatomy 0.000 description 5
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 102400000344 Angiotensin-1 Human genes 0.000 description 4
- 101800000734 Angiotensin-1 Proteins 0.000 description 4
- -1 Fosin Prily Chemical compound 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 4
- 108010002350 Interleukin-2 Proteins 0.000 description 4
- 102000000588 Interleukin-2 Human genes 0.000 description 4
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 4
- 210000004241 Th2 cell Anatomy 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 210000000577 adipose tissue Anatomy 0.000 description 4
- 239000000556 agonist Substances 0.000 description 4
- ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 4
- 230000007783 downstream signaling Effects 0.000 description 4
- 230000004064 dysfunction Effects 0.000 description 4
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 4
- 210000002683 foot Anatomy 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 238000011532 immunohistochemical staining Methods 0.000 description 4
- 230000001506 immunosuppresive effect Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 238000001000 micrograph Methods 0.000 description 4
- 239000003973 paint Substances 0.000 description 4
- 231100000915 pathological change Toxicity 0.000 description 4
- 230000036285 pathological change Effects 0.000 description 4
- 239000000700 radioactive tracer Substances 0.000 description 4
- 238000001959 radiotherapy Methods 0.000 description 4
- 231100000241 scar Toxicity 0.000 description 4
- 238000012289 standard assay Methods 0.000 description 4
- CDKIEBFIMCSCBB-UHFFFAOYSA-N 1-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)-3-(1-methyl-2-phenylpyrrolo[2,3-b]pyridin-3-yl)prop-2-en-1-one;hydrochloride Chemical compound Cl.C1C=2C=C(OC)C(OC)=CC=2CCN1C(=O)C=CC(C1=CC=CN=C1N1C)=C1C1=CC=CC=C1 CDKIEBFIMCSCBB-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 206010061818 Disease progression Diseases 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101001025337 Homo sapiens High mobility group protein B1 Proteins 0.000 description 3
- 102000008070 Interferon-gamma Human genes 0.000 description 3
- 108010050904 Interferons Proteins 0.000 description 3
- 102000014150 Interferons Human genes 0.000 description 3
- 101150051655 Lyz2 gene Proteins 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 241000500121 Mirax Species 0.000 description 3
- 239000004264 Petrolatum Substances 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- GKLVYJBZJHMRIY-OUBTZVSYSA-N Technetium-99 Chemical compound [99Tc] GKLVYJBZJHMRIY-OUBTZVSYSA-N 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000012085 chronic inflammatory response Effects 0.000 description 3
- 238000012790 confirmation Methods 0.000 description 3
- 230000008602 contraction Effects 0.000 description 3
- 210000004207 dermis Anatomy 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 230000005750 disease progression Effects 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 210000005069 ears Anatomy 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 230000000893 fibroproliferative effect Effects 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 229960003130 interferon gamma Drugs 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 238000002587 lymphangiography Methods 0.000 description 3
- 238000011271 lymphoscintigraphy Methods 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 238000003333 near-infrared imaging Methods 0.000 description 3
- 210000004789 organ system Anatomy 0.000 description 3
- 239000012188 paraffin wax Substances 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 230000002085 persistent effect Effects 0.000 description 3
- 229940066842 petrolatum Drugs 0.000 description 3
- 235000019271 petrolatum Nutrition 0.000 description 3
- 230000002980 postoperative effect Effects 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 230000000750 progressive effect Effects 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- 230000037390 scarring Effects 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 210000004003 subcutaneous fat Anatomy 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- 230000008733 trauma Effects 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 229940099259 vaseline Drugs 0.000 description 3
- 230000007998 vessel formation Effects 0.000 description 3
- 101100339431 Arabidopsis thaliana HMGB2 gene Proteins 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 108700010013 HMGB1 Proteins 0.000 description 2
- 101150021904 HMGB1 gene Proteins 0.000 description 2
- 102000018932 HSP70 Heat-Shock Proteins Human genes 0.000 description 2
- 108010027992 HSP70 Heat-Shock Proteins Proteins 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 102100022297 Integrin alpha-X Human genes 0.000 description 2
- 102000004388 Interleukin-4 Human genes 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 101150028321 Lck gene Proteins 0.000 description 2
- 101000839464 Leishmania braziliensis Heat shock 70 kDa protein Proteins 0.000 description 2
- 206010052315 Lymphatic obstruction Diseases 0.000 description 2
- 102100025748 Mothers against decapentaplegic homolog 3 Human genes 0.000 description 2
- 101710143111 Mothers against decapentaplegic homolog 3 Proteins 0.000 description 2
- 101600105505 Mus musculus Vascular endothelial growth factor C (isoform 1) Proteins 0.000 description 2
- OKJIRPAQVSHGFK-UHFFFAOYSA-N N-acetylglycine Chemical compound CC(=O)NCC(O)=O OKJIRPAQVSHGFK-UHFFFAOYSA-N 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 101710111747 Peptidyl-prolyl cis-trans isomerase FKBP12 Proteins 0.000 description 2
- 238000010240 RT-PCR analysis Methods 0.000 description 2
- 208000035415 Reinfection Diseases 0.000 description 2
- 108010011005 STAT6 Transcription Factor Proteins 0.000 description 2
- 102100023980 Signal transducer and activator of transcription 6 Human genes 0.000 description 2
- 206010040867 Skin hypertrophy Diseases 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 230000006044 T cell activation Effects 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 210000003484 anatomy Anatomy 0.000 description 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 2
- 229940003587 aquaphor Drugs 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 230000036765 blood level Effects 0.000 description 2
- 229940046731 calcineurin inhibitors Drugs 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 239000002771 cell marker Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 2
- 101150070926 ct gene Proteins 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000000890 drug combination Substances 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000000548 hind-foot Anatomy 0.000 description 2
- 230000036732 histological change Effects 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 229940028885 interleukin-4 Drugs 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 210000003563 lymphoid tissue Anatomy 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 206010033675 panniculitis Diseases 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 238000010149 post-hoc-test Methods 0.000 description 2
- 230000002206 pro-fibrotic effect Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 230000000541 pulsatile effect Effects 0.000 description 2
- 238000010244 region-of-interest analysis Methods 0.000 description 2
- 238000002271 resection Methods 0.000 description 2
- 230000004043 responsiveness Effects 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 238000002603 single-photon emission computed tomography Methods 0.000 description 2
- 206010040872 skin infection Diseases 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 210000004304 subcutaneous tissue Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 238000009121 systemic therapy Methods 0.000 description 2
- 238000002626 targeted therapy Methods 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 229940056501 technetium 99m Drugs 0.000 description 2
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229960002051 trandolapril Drugs 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 238000012800 visualization Methods 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 230000037314 wound repair Effects 0.000 description 2
- JNELGWHKGNBSMD-UHFFFAOYSA-N xanthone Chemical compound C1=CC=C2C(=O)C3=CC=CC=C3OC2=C1 JNELGWHKGNBSMD-UHFFFAOYSA-N 0.000 description 2
- MTZBBNMLMNBNJL-UHFFFAOYSA-N xipamide Chemical compound CC1=CC=CC(C)=C1NC(=O)C1=CC(S(N)(=O)=O)=C(Cl)C=C1O MTZBBNMLMNBNJL-UHFFFAOYSA-N 0.000 description 2
- CUKWUWBLQQDQAC-VEQWQPCFSA-N (3s)-3-amino-4-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s,3s)-1-[[(2s)-1-[(2s)-2-[[(1s)-1-carboxyethyl]carbamoyl]pyrrolidin-1-yl]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-ox Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 CUKWUWBLQQDQAC-VEQWQPCFSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- NWQGDIBCFLDHDO-UHFFFAOYSA-N 4-[3-(2-chloro-4,5-difluoro-benzoyl)ureido]-3-trifluoromethoxybenzoic acid Chemical compound FC(F)(F)OC1=CC(C(=O)O)=CC=C1NC(=O)NC(=O)C1=CC(F)=C(F)C=C1Cl NWQGDIBCFLDHDO-UHFFFAOYSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 239000012099 Alexa Fluor family Substances 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- 102000004631 Calcineurin Human genes 0.000 description 1
- 108010042955 Calcineurin Proteins 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 108010051219 Cre recombinase Proteins 0.000 description 1
- 229920001076 Cutan Polymers 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 108010052167 Dihydroorotate Dehydrogenase Proteins 0.000 description 1
- 102100032823 Dihydroorotate dehydrogenase (quinone), mitochondrial Human genes 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 102100038595 Estrogen receptor Human genes 0.000 description 1
- 101150009958 FLT4 gene Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 1
- 101000712669 Homo sapiens TGF-beta receptor type-2 Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 102100022338 Integrin alpha-M Human genes 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- XUIIKFGFIJCVMT-LBPRGKRZSA-N L-thyroxine Chemical compound IC1=CC(C[C@H]([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-LBPRGKRZSA-N 0.000 description 1
- 208000000185 Localized scleroderma Diseases 0.000 description 1
- 101710132699 Lysozyme 2 Proteins 0.000 description 1
- 241001139947 Mida Species 0.000 description 1
- 101100490443 Mus musculus Acvr1 gene Proteins 0.000 description 1
- 102000004722 NADPH Oxidases Human genes 0.000 description 1
- 108010002998 NADPH Oxidases Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010030124 Oedema peripheral Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 102100037265 Podoplanin Human genes 0.000 description 1
- 101710118150 Podoplanin Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- YIQKLZYTHXTDDT-UHFFFAOYSA-H Sirius red F3B Chemical compound C1=CC(=CC=C1N=NC2=CC(=C(C=C2)N=NC3=C(C=C4C=C(C=CC4=C3[O-])NC(=O)NC5=CC6=CC(=C(C(=C6C=C5)[O-])N=NC7=C(C=C(C=C7)N=NC8=CC=C(C=C8)S(=O)(=O)[O-])S(=O)(=O)[O-])S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)[O-])S(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+] YIQKLZYTHXTDDT-UHFFFAOYSA-H 0.000 description 1
- 206010040830 Skin discomfort Diseases 0.000 description 1
- 206010050207 Skin fibrosis Diseases 0.000 description 1
- 208000016247 Soft tissue disease Diseases 0.000 description 1
- 241001647839 Streptomyces tsukubensis Species 0.000 description 1
- 241000583281 Sugiura Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 102100033455 TGF-beta receptor type-2 Human genes 0.000 description 1
- 108091005735 TGF-beta receptors Proteins 0.000 description 1
- 101150000629 TGFB1 gene Proteins 0.000 description 1
- 238000012233 TRIzol extraction Methods 0.000 description 1
- 210000000447 Th1 cell Anatomy 0.000 description 1
- 102000016715 Transforming Growth Factor beta Receptors Human genes 0.000 description 1
- 102000011117 Transforming Growth Factor beta2 Human genes 0.000 description 1
- 101800000304 Transforming growth factor beta-2 Proteins 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 102000016663 Vascular Endothelial Growth Factor Receptor-3 Human genes 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 241000021375 Xenogenes Species 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 229950010741 aceturate Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- ZDQSOHOQTUFQEM-PKUCKEGBSA-N ascomycin Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C\C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@@H](O)[C@H](OC)C1 ZDQSOHOQTUFQEM-PKUCKEGBSA-N 0.000 description 1
- ZDQSOHOQTUFQEM-XCXYXIJFSA-N ascomycin Natural products CC[C@H]1C=C(C)C[C@@H](C)C[C@@H](OC)[C@H]2O[C@@](O)([C@@H](C)C[C@H]2OC)C(=O)C(=O)N3CCCC[C@@H]3C(=O)O[C@H]([C@H](C)[C@@H](O)CC1=O)C(=C[C@@H]4CC[C@@H](O)[C@H](C4)OC)C ZDQSOHOQTUFQEM-XCXYXIJFSA-N 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 230000006472 autoimmune response Effects 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 230000037319 collagen production Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000010226 confocal imaging Methods 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 229960000956 coumarin Drugs 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 108010017271 denileukin diftitox Proteins 0.000 description 1
- 229960002923 denileukin diftitox Drugs 0.000 description 1
- 210000003298 dental enamel Anatomy 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 239000012502 diagnostic product Substances 0.000 description 1
- 239000012954 diazonium Substances 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-O diazynium Chemical compound [NH+]#N IJGRMHOSHXDMSA-UHFFFAOYSA-O 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 210000000959 ear middle Anatomy 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- OYFJQPXVCSSHAI-QFPUQLAESA-N enalapril maleate Chemical compound OC(=O)\C=C/C(O)=O.C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 OYFJQPXVCSSHAI-QFPUQLAESA-N 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 238000011327 histological measurement Methods 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000000642 iatrogenic effect Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 238000011503 in vivo imaging Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000003331 infrared imaging Methods 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229950008325 levothyroxine Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
- 230000003692 lymphatic flow Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000004995 male reproductive system Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 210000000452 mid-foot Anatomy 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000002346 musculoskeletal system Anatomy 0.000 description 1
- 206010028537 myelofibrosis Diseases 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000011422 pharmacological therapy Methods 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 208000005333 pulmonary edema Diseases 0.000 description 1
- 230000006824 pyrimidine synthesis Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 201000002793 renal fibrosis Diseases 0.000 description 1
- 230000036454 renin-angiotensin system Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000013424 sirius red staining Methods 0.000 description 1
- 230000029547 smooth muscle hypertrophy Effects 0.000 description 1
- 244000000000 soil microbiome Species 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
- 230000003868 tissue accumulation Effects 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000023750 transforming growth factor beta production Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000012301 transgenic model Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 238000007492 two-way ANOVA Methods 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 239000002966 varnish Substances 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
- 239000011686 zinc sulphate Substances 0.000 description 1
- 235000009529 zinc sulphate Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562112273P | 2015-02-05 | 2015-02-05 | |
| US62/112,273 | 2015-02-05 | ||
| PCT/US2016/016680 WO2016127013A1 (en) | 2015-02-05 | 2016-02-05 | Compositions and methods for treatment of edema |
| CN201680016894.0A CN107427007B (zh) | 2015-02-05 | 2016-02-05 | 用于治疗水肿的组合物和方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201680016894.0A Division CN107427007B (zh) | 2015-02-05 | 2016-02-05 | 用于治疗水肿的组合物和方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114588154A true CN114588154A (zh) | 2022-06-07 |
Family
ID=56564721
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210078205.6A Pending CN114588154A (zh) | 2015-02-05 | 2016-02-05 | 用于治疗水肿的组合物和方法 |
| CN201680016894.0A Expired - Fee Related CN107427007B (zh) | 2015-02-05 | 2016-02-05 | 用于治疗水肿的组合物和方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201680016894.0A Expired - Fee Related CN107427007B (zh) | 2015-02-05 | 2016-02-05 | 用于治疗水肿的组合物和方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (5) | US10251871B2 (enExample) |
| EP (1) | EP3253211B1 (enExample) |
| JP (2) | JP6704403B2 (enExample) |
| CN (2) | CN114588154A (enExample) |
| AU (2) | AU2016215173B2 (enExample) |
| CA (1) | CA2975879A1 (enExample) |
| ES (1) | ES3040783T3 (enExample) |
| HK (1) | HK1247789A1 (enExample) |
| WO (1) | WO2016127013A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HK1247789A1 (zh) * | 2015-02-05 | 2018-10-05 | Memorial Sloan Kettering Cancer Center | 用於治疗水肿的组合物和方法 |
| EP3500308A4 (en) * | 2016-08-18 | 2020-04-22 | Memorial Sloan Kettering Cancer Center | INHIBITION OF THE SPHINGOSIN-1-PHOSPHATE RECEPTOR FOR TREATING AND PREVENTING LYMPHEDEMES |
| MX2021002916A (es) * | 2018-09-14 | 2021-08-24 | Puretech Lyt 100 Inc | Pirfenidona enriquecida con deuterio y métodos para su uso. |
| EP3876905A4 (en) * | 2018-11-05 | 2022-08-03 | Apramitha Innovations Private Limited | Teriflunomide topical pharmaceutical compositions |
| WO2021186401A1 (en) * | 2020-03-18 | 2021-09-23 | Puretech Lyt 100, Inc. | Methods of treating lymphedema with deupirfenidone |
| CN112642065B (zh) * | 2020-12-28 | 2022-08-02 | 锐可医疗科技(上海)有限公司 | 激光治疗仪及存储介质 |
| WO2024059336A1 (en) * | 2022-09-18 | 2024-03-21 | Memorial Sloan Kettering Cancer Center | Inhibition of protease-activated receptor 2 (par2) pathway for treatment and prevention of lymphedema |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102209543A (zh) * | 2008-11-10 | 2011-10-05 | 英特芒尼公司 | 用于具有非典型肝功能的患者的吡非尼酮治疗 |
| US20110288134A1 (en) * | 2008-10-29 | 2011-11-24 | Pacific Therapeutics Ltd. | Composition and method for treating fibrosis |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005011669A1 (ja) * | 2003-08-05 | 2005-02-10 | Dainippon Sumitomo Pharma Co., Ltd. | 経皮投与用医薬組成物 |
| US20050158371A1 (en) * | 2002-02-12 | 2005-07-21 | Sumitomo Pharmaceuticals Co., Ltd. | Novel external agent |
| US7232828B2 (en) * | 2002-08-10 | 2007-06-19 | Bethesda Pharmaceuticals, Inc. | PPAR Ligands that do not cause fluid retention, edema or congestive heart failure |
| WO2007103687A2 (en) * | 2006-03-01 | 2007-09-13 | Tristrata, Inc. | Composition and method for topical treatment of tar-responsive dermatological disorders |
| CN101443004B (zh) * | 2006-03-23 | 2013-03-06 | 参天制药株式会社 | 用于与血管通透性有关的疾病或病症的制剂 |
| EP2036555B1 (en) * | 2006-06-15 | 2011-11-16 | Shanghai Genomics, Inc. | The use of pyridone derivatives for preventing and treating radiation injury of lungs |
| CA2823407C (en) * | 2007-03-22 | 2016-10-18 | Berg Pharma Llc | Topical formulations having enhanced bioavailability |
| WO2010091140A1 (en) * | 2009-02-04 | 2010-08-12 | Bipar Sciences, Inc. | Treatment of lung cancer with a parp inhibitor in combination with a growth factor inhibitor |
| DE102010015143A1 (de) * | 2010-04-16 | 2011-10-20 | Cts Chemical Industries Ltd. | Stabile flüssige ölige gebrauchsfertige Formulierungen, Herstellung davon und Verwendung davon |
| HK1247789A1 (zh) * | 2015-02-05 | 2018-10-05 | Memorial Sloan Kettering Cancer Center | 用於治疗水肿的组合物和方法 |
| US10292961B2 (en) * | 2015-07-15 | 2019-05-21 | Hangzhou Dac Biotech Co., Ltd. | Disulfur bridge linkers for conjugation of a cell-binding molecule |
-
2016
- 2016-02-05 HK HK18107279.7A patent/HK1247789A1/zh unknown
- 2016-02-05 CA CA2975879A patent/CA2975879A1/en active Pending
- 2016-02-05 EP EP16747309.9A patent/EP3253211B1/en active Active
- 2016-02-05 JP JP2017541301A patent/JP6704403B2/ja not_active Expired - Fee Related
- 2016-02-05 AU AU2016215173A patent/AU2016215173B2/en active Active
- 2016-02-05 US US15/549,156 patent/US10251871B2/en active Active
- 2016-02-05 CN CN202210078205.6A patent/CN114588154A/zh active Pending
- 2016-02-05 ES ES16747309T patent/ES3040783T3/es active Active
- 2016-02-05 CN CN201680016894.0A patent/CN107427007B/zh not_active Expired - Fee Related
- 2016-02-05 WO PCT/US2016/016680 patent/WO2016127013A1/en not_active Ceased
-
2019
- 2019-02-15 US US16/277,942 patent/US10874651B2/en active Active
-
2020
- 2020-02-18 AU AU2020201161A patent/AU2020201161B2/en active Active
- 2020-03-12 JP JP2020042965A patent/JP6926263B2/ja not_active Expired - Fee Related
- 2020-11-17 US US16/950,652 patent/US11583523B2/en active Active
-
2023
- 2023-01-27 US US18/102,437 patent/US12144805B2/en active Active
-
2024
- 2024-10-12 US US18/914,163 patent/US20250235436A1/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110288134A1 (en) * | 2008-10-29 | 2011-11-24 | Pacific Therapeutics Ltd. | Composition and method for treating fibrosis |
| CN102209543A (zh) * | 2008-11-10 | 2011-10-05 | 英特芒尼公司 | 用于具有非典型肝功能的患者的吡非尼酮治疗 |
Non-Patent Citations (1)
| Title |
|---|
| NICHOLAS W. CLAVIN: "TGF-β1 is a negative regulator of lymphatic regeneration during wound repair", AJP - HEART AND CIRCULATORY PHYSIOLOGY, vol. 295, pages 2113 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107427007A (zh) | 2017-12-01 |
| US20230241043A1 (en) | 2023-08-03 |
| ES3040783T3 (en) | 2025-11-04 |
| JP6926263B2 (ja) | 2021-08-25 |
| AU2020201161B2 (en) | 2021-07-15 |
| JP2020114830A (ja) | 2020-07-30 |
| WO2016127013A1 (en) | 2016-08-11 |
| US10251871B2 (en) | 2019-04-09 |
| US20250235436A1 (en) | 2025-07-24 |
| HK1247789A1 (zh) | 2018-10-05 |
| EP3253211A1 (en) | 2017-12-13 |
| CN107427007B (zh) | 2022-02-11 |
| CA2975879A1 (en) | 2016-08-11 |
| EP3253211A4 (en) | 2018-10-31 |
| AU2020201161A1 (en) | 2020-03-05 |
| US12144805B2 (en) | 2024-11-19 |
| EP3253211B1 (en) | 2025-06-11 |
| JP2018504436A (ja) | 2018-02-15 |
| JP6704403B2 (ja) | 2020-06-03 |
| US20210069164A1 (en) | 2021-03-11 |
| AU2016215173A1 (en) | 2017-08-24 |
| US20180028514A1 (en) | 2018-02-01 |
| US20200016137A1 (en) | 2020-01-16 |
| AU2016215173B2 (en) | 2019-11-21 |
| US11583523B2 (en) | 2023-02-21 |
| US10874651B2 (en) | 2020-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12144805B2 (en) | Compositions and methods for treatment of edema | |
| CA3033863C (en) | Inhibition of sphingosine 1-phosphate receptor for treatment and prevention of lymphedema | |
| US20250255877A1 (en) | Compositions and methods for immune-mediated cancer therapy | |
| EP4132954A1 (en) | Use of cdon inhibitors for the treatment of endothelial dysfunction | |
| US20220088015A1 (en) | Methods and pharmaceutical compositions for the treatment of age-related cardiometabolic diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20220607 |
|
| WD01 | Invention patent application deemed withdrawn after publication |